Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers: A gastroscopic study

Scandinavian Journal of Gastroenterology

Volumn 35, Issue 5, 2000, Pages 464-469

  Fork, Frans Thomas ^a,b   Lafolie, P ^a,b   Toth E ^a,b   Lindgarde F ^a,b  

^a Sanofi Winthrop   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Aspirin; Clopidogrel; Gastroscopy; Tolerability

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DUODENUM MUCOSA; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROSCOPY; HUMAN; HUMAN EXPERIMENT; ISCHEMIA; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH EROSION; STOMACH MUCOSA;

EID: 0034048238     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655200750023705     Document Type: Article

References (18)

1. 1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
2. 2. Savi P, Heilmann E, Nurden P, Laplace MC, Bihour C, Kiefer G, et al. Clopidogrel: an antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clin Appl Thromb Hemost 1996;2:35-42.
3. 3. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971;231: 232-5.
4. 4. Robert A. Cytoprotection by prostaglandins. Gastroenterology 1979;77:761-7.
5. 5. Davenport HW, Warner HA, Code CF. Functional significance of gastric mucosal barrier to sodium. Gastroenterology 1964;47: 142-52.
6. 6. Bogousslavsky J. Lower gastrointestinal bleeding with clopidogrel compared with aspirin. Cerebrovasc Dis 1998;8 Suppl 4:43.
7. 7. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ 1990;300:278-84.
8. 8. Lanza FL, Royer GL Jr, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 1980;303:136-8.
9. 9. Lanza FL. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal anti-inflammatory agents. Am J Med 1984;77:19-24.
10. 10. Simon B, Kleinsorge H, Muller P. Vergleich der gastroduodenalen verträglichkeit von ticlopidine und acetylsalicylsäure. Dtsch Med Wochenschr 1993;188:1146-9.
11. 11. Hirsh J, Dalen JE, Fuster V, Harker L, Patrono C, Roth GJ. Aspirin and other platelet-active drugs: the relationship between dose, effectiveness and side-effects. Chest 1995;108 Suppl: S247-57.
12. 12. Stalnikowicz-Darvasi R. Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis. J Clin Gastroenterol 1995;21:13-6.
13. 13. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-30.
14. 14. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric coated or buffered product. Lancet 1996;348:1413-6.
15. 15. Dyken ML. Aspirin dose in secondary prevention of stroke. Cerebrovasc Dis 1998;8:361-2.
16. 16. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
17. 17. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effect of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;361:1755-62.
18. 18. Grossman CM. NSAIDs and gut toxicity. Lancet 1994;344:57.